Literature DB >> 226884

Activation of suppressor T cells during Epstein-Barr-virus-induced infectious mononucleosis.

G Tosato, I Magrath, I Koski, N Dooley, M Blaese.   

Abstract

Infectious mononucleosis is caused by the Epstein-Barr virus (EBV), an unusual human pathogen because it preferentially infects B lymphocytes and consequently activates them to produce immunoglobulins. When cultures of lymphocytes from patients with infectious mononucleosis were stimulated with polyclonal activators, unseparated cells failed to produce immunoglobulins, whereas purified B cells responded normally. Cocultures demonstrated profound suppressor T-cell activity in blood from patients with infectious mononucleosis. Early in this disease, circulating immunoglobulin-secreting cells were elevated, but during the second week their number was strikingly depressed. These data indicate that during infectious mononucleosis, EBV causes polyclonal activation of B cells, reflected by hypergammaglobulinemia and increased circulating immunoglobulin-secreting cells. Next, suppressor T cells become activated and inhibit further B-cell activation. Thus, activation of suppressor T cells in infectious mononucleosis provides a unique additional mechanism of host defense because these T cells inhibit the activation and proliferation of an important target of the causative virus.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 226884     DOI: 10.1056/NEJM197911223012101

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  63 in total

Review 1.  Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma.

Authors:  G Niedobitek
Journal:  Mol Pathol       Date:  2000-10

Review 2.  Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.

Authors:  R J O'Reilly; T N Small; E Papadopoulos; K Lucas; J Lacerda; L Koulova
Journal:  Springer Semin Immunopathol       Date:  1998

Review 3.  Regulation of T cell activation by leukotriene B4.

Authors:  J S Goodwin
Journal:  Immunol Res       Date:  1986       Impact factor: 2.829

4.  Immune function in chronic active Epstein-Barr virus infection.

Authors:  R Kibler; D O Lucas; M J Hicks; B T Poulos; J F Jones
Journal:  J Clin Immunol       Date:  1985-01       Impact factor: 8.317

5.  Generation of B suppressor cells by phytohaemagglutinin.

Authors:  R Farkas; Y Manor; A Klajman
Journal:  Immunology       Date:  1986-03       Impact factor: 7.397

Review 6.  Epstein-Barr virus, infectious mononucleosis, and posttransplant lymphoproliferative disorders.

Authors:  M A Nalesnik; T E Starzl
Journal:  Transplant Sci       Date:  1994-09

7.  Epstein-Barr virus (EBV) recombinants: use of positive selection markers to rescue mutants in EBV-negative B-lymphoma cells.

Authors:  F Wang; A Marchini; E Kieff
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

8.  Phenotypic characterization of CD8+ T cell populations in HIV disease and in anti-HIV immunity.

Authors:  K C Watret; J A Whitelaw; K S Froebel; A G Bird
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

9.  HCV infection in patients with primary defects of immunoglobulin production.

Authors:  I Quinti; F Pandolfi; R Paganelli; D el Salman; A Giovannetti; R Rosso; A Oliva; L Rainaldi; F Aiuti
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

10.  Pure red cell aplasia in a patient with trisomy X chromosome abnormality and reactivated Epstein-Barr virus infection.

Authors:  Masanori Daibata; Hisanori Machida; Yuiko Nemoto; Hirokuni Taguchi
Journal:  Int J Hematol       Date:  2003-05       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.